Here, we explored continuous and pulsatile dosing strategies in an EGFR-mutant GBM cell line, and used mathematical and statistical modeling to determine optimal lapatinib dosing schedules for inhibiting tumor growth. This evidence concerns the gene EGFR and glioblastoma.